CUMBERLAND PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.76 USD | +3.53% |
|
+10.00% | -1.77% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 93.63 | 78.2 | 44.3 | 68.9 | 32.54 | 26.7 |
| Enterprise Value (EV) 1 | 77.4 | 71.48 | 36.62 | 57.92 | 33.75 | 26.81 |
| P/E ratio | -13.4 x | -22.4 x | -13.4 x | -19.8 x | -5.88 x | -4.07 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 2.3 x | 1.65 x | 1.18 x | 1.91 x | 0.77 x | 0.68 x |
| EV / Revenue | 1.9 x | 1.5 x | 0.98 x | 1.61 x | 0.8 x | 0.68 x |
| EV / EBITDA | -17.6 x | 91.5 x | -22.4 x | -18.9 x | -89.6 x | -21 x |
| EV / FCF | 67.1 x | -60.3 x | -19.5 x | 160 x | 14 x | 2.87 x |
| FCF Yield | 1.49% | -1.66% | -5.12% | 0.62% | 7.12% | 34.8% |
| Price to Book | 1.67 x | 1.54 x | 0.94 x | 1.61 x | 0.89 x | 0.85 x |
| Nbr of stocks (in thousands) | 15,528 | 15,184 | 15,017 | 14,755 | 14,464 | 14,905 |
| Reference price 2 | 6.030 | 5.150 | 2.950 | 4.670 | 2.250 | 1.792 |
| Announcement Date | 3/12/19 | 3/20/20 | 3/12/21 | 3/11/22 | 3/13/23 | 3/13/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 40.74 | 47.53 | 37.44 | 35.99 | 42.01 | 39.55 |
| EBITDA 1 | -4.408 | 0.7812 | -1.633 | -3.071 | -0.3768 | -1.275 |
| EBIT 1 | -7.391 | -3.623 | -6.382 | -7.677 | -5.705 | -6.211 |
| Operating Margin | -18.14% | -7.62% | -17.04% | -21.34% | -13.58% | -15.7% |
| Earnings before Tax (EBT) 1 | -7.022 | -3.626 | -6.57 | -5.562 | -5.581 | -6.285 |
| Net income 1 | -6.963 | -3.538 | -3.339 | -3.508 | -5.57 | -6.279 |
| Net margin | -17.09% | -7.44% | -8.92% | -9.75% | -13.26% | -15.88% |
| EPS 2 | -0.4500 | -0.2300 | -0.2202 | -0.2362 | -0.3825 | -0.4400 |
| Free Cash Flow 1 | 1.153 | -1.186 | -1.877 | 0.3613 | 2.403 | 9.33 |
| FCF margin | 2.83% | -2.49% | -5.01% | 1% | 5.72% | 23.59% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/12/19 | 3/20/20 | 3/12/21 | 3/11/22 | 3/13/23 | 3/13/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 1.2 | 0.11 |
| Net Cash position 1 | 16.2 | 6.72 | 7.68 | 11 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -3.188 x | -0.0838 x |
| Free Cash Flow 1 | 1.15 | -1.19 | -1.88 | 0.36 | 2.4 | 9.33 |
| ROE (net income / shareholders' equity) | -11.8% | -6.65% | -13.5% | -12.5% | -14.4% | -19.4% |
| ROA (Net income/ Total Assets) | -4.49% | -2.08% | -3.97% | -5.3% | -4.02% | -4.44% |
| Assets 1 | 155.2 | 169.7 | 84.15 | 66.13 | 138.6 | 141.3 |
| Book Value Per Share 2 | 3.610 | 3.350 | 3.140 | 2.900 | 2.520 | 2.100 |
| Cash Flow per Share 2 | 1.800 | 1.850 | 1.650 | 1.830 | 1.380 | 1.300 |
| Capex 1 | 0.46 | 0.25 | 0.14 | 0.1 | 0.1 | 0.28 |
| Capex / Sales | 1.12% | 0.52% | 0.38% | 0.29% | 0.24% | 0.71% |
| Announcement Date | 3/12/19 | 3/20/20 | 3/12/21 | 3/11/22 | 3/13/23 | 3/13/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -1.77% | 24.95M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- CPIX Stock
- Financials Cumberland Pharmaceuticals Inc.
